Long-term results of suppressing thyroid-stimulating hormone during radiotherapy to prevent primary hypothyroidism in medulloblastoma/PNET and Hodgkin lymphoma: a prospective cohort study

Maura MASSIMINO; Marta PODDA; Lorenza GANDOLA; Emanuele PIGNOLI; Ettore SEREGNI; Carlo MOROSI; Filippo SPREAFICO; Andrea FERRARI; Emilia PECORI; Monica TERENZIANI.
Frontiers of Medicine ; (4): 101-107, 2021.
Artículo en Inglés | WPRIM | ID: wpr-880948

Documentos relacionados

  1. Long-term results of suppressing thyroid-stimulating hormone during radiotherapy to prevent primary hypothyroidism in medulloblastoma/PNET and Hodgkin lymphoma: a prospective cohort study.
  2. Types of deviation and review criteria in pretreatment central quality control of tumor bed boost in medulloblastoma-an analysis of the German Radiotherapy Quality Control Panel in the SIOP PNET5 MB trial.
  3. Craniospinal irradiation as part of re-irradiation for children with recurrent medulloblastoma.
  4. In Vivo Radiobiological Investigations with the TOP-IMPLART Proton Beam on a Medulloblastoma Mouse Model.
  5. The impact of nutritional counseling on thyroid disorders in head and neck cancer patients after (chemo)radiotherapy: results from a prospective interventional trial.
  6. Molecular characterization of long-term survivors of metastatic medulloblastoma treated with reduced-dose craniospinal irradiation.
  7. FANCD2 deficiency sensitizes SHH medulloblastoma to radiotherapy via ferroptosis.
  8. Proton therapy for adult medulloblastoma: Acute toxicity and disease control outcomes.
  9. Comparison of hypothyroidism, growth hormone deficiency, and adrenal insufficiency following proton and photon radiotherapy in children with medulloblastoma.
  10. Implementation of a DVH Registry to provide constraints and continuous quality monitoring for pediatric CSI treatment planning.